Stock Traders Purchase Large Volume of Cytokinetics Call Options (NASDAQ:CYTK)

Cytokinetics, Incorporated (NASDAQ:CYTK) was the target of some unusual options trading on Tuesday. Stock traders acquired 16,357 call options on the stock. This is an increase of 260% compared to the average volume of 4,543 call options.

Insider Buying and Selling

In related news, EVP Fady Ibraham Malik sold 12,033 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $62.15, for a total transaction of $747,850.95. Following the transaction, the executive vice president directly owned 153,902 shares of the company’s stock, valued at approximately $9,565,009.30. The trade was a 7.25% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Andrew Callos sold 26,000 shares of the business’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $61.87, for a total value of $1,608,620.00. Following the transaction, the executive vice president directly owned 50,440 shares in the company, valued at $3,120,722.80. This trade represents a 34.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 169,976 shares of company stock valued at $10,710,369. Corporate insiders own 2.60% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in CYTK. Lisanti Capital Growth LLC purchased a new stake in shares of Cytokinetics during the third quarter valued at $2,697,000. Vanguard Group Inc. lifted its holdings in shares of Cytokinetics by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 12,048,131 shares of the biopharmaceutical company’s stock valued at $765,538,000 after purchasing an additional 191,336 shares during the last quarter. Hudson Bay Capital Management LP lifted its holdings in shares of Cytokinetics by 15.4% during the third quarter. Hudson Bay Capital Management LP now owns 182,131 shares of the biopharmaceutical company’s stock valued at $10,010,000 after purchasing an additional 24,345 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in shares of Cytokinetics during the third quarter valued at $1,359,000. Finally, Knott David M Jr purchased a new stake in shares of Cytokinetics during the third quarter valued at $1,649,000.

Wall Street Analyst Weigh In

CYTK has been the topic of several recent research reports. Mizuho boosted their price target on Cytokinetics from $84.00 to $100.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 18th. Royal Bank Of Canada upped their target price on Cytokinetics from $101.00 to $119.00 and gave the company an “outperform” rating in a research report on Wednesday, May 6th. Stifel Nicolaus upped their target price on Cytokinetics from $98.00 to $108.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. UBS Group set a $119.00 target price on Cytokinetics in a research report on Wednesday, May 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cytokinetics in a research report on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Cytokinetics has a consensus rating of “Moderate Buy” and an average price target of $98.55.

Cytokinetics Stock Performance

Shares of NASDAQ CYTK traded up $0.05 during trading on Thursday, reaching $77.27. The stock had a trading volume of 444,608 shares, compared to its average volume of 2,221,586. Cytokinetics has a one year low of $29.31 and a one year high of $80.20. The stock has a market cap of $9.61 billion, a PE ratio of -11.33 and a beta of 0.38. The firm’s 50 day moving average price is $65.30 and its two-hundred day moving average price is $64.38.

Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.67) earnings per share for the quarter, meeting analysts’ consensus estimates of ($1.67). The firm had revenue of $19.36 million during the quarter, compared to the consensus estimate of $8.52 million. Cytokinetics’s revenue was up 1112.5% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.36) earnings per share. On average, research analysts expect that Cytokinetics will post -6.31 earnings per share for the current year.

Key Headlines Impacting Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: JPMorgan raised its price target on Cytokinetics to $97 from $92 and maintained an overweight rating, signaling confidence in further upside. Cytokinetics (NASDAQ:CYTK) Given New $97.00 Price Target at JPMorgan Chase & Co.
• Positive Sentiment: HC Wainwright reiterated a Buy rating and $140 price target while nudging up near-term EPS estimates for Q2, Q3, and Q4 2026, which suggests analysts see the company performing better than previously expected. Cytokinetics analyst estimate updates
• Positive Sentiment: Unusually heavy call-option buying was reported, with traders purchasing far more calls than normal, often a sign of bullish speculation ahead of a catalyst. Cytokinetics Target of Unusually High Options Trading (NASDAQ:CYTK)
• Neutral Sentiment: Cytokinetics said it will host its third annual CLIMB muscle biology symposium on May 29, a scientific event that supports its research profile but does not appear to be a major near-term commercial catalyst. Cytokinetics to Host Annual Symposium on Contemporary Landscapes in Muscle Biology (CLIMB)
• Neutral Sentiment: The company also announced participation in the RBC Capital Markets Global Healthcare Conference, which keeps management visible to investors but is typically more of a communications event than a stock-moving catalyst. Cytokinetics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

About Cytokinetics

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.